The Effect of Teaching HIV-Infected Patients About HIV and Treatment

Inclusion Criteria Patients must have: * Documented and confirmed HIV infection. * Limited or no experience with antiretrovirals. * CD4+ lymphocyte cell count of 50 cells/mm3 or more 14 days prior to study drug administration. * HIV-1 plasma RNA above 40 copies/ml and less than 100,000 copies/ml within 14 days prior to study drug administration. * Ability to read, comprehend, and record information in fifth-grade English. * Ability to attend the 4 sessions of T.H.E. course on Weeks 1-4. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Patients suffering from a serious medical condition such as diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction which would compromise the safety of the patient. * Malabsorption syndrome or other gastrointestinal dysfunction which may interfere with drug absorption or render the patient unable to take oral medication. * Acute or chronic active hepatitis. Concurrent Treatment: Excluded: Treatment with foscarnet or other agents with required documented activity against HIV-1 in vitro. Patients with the following prior conditions are excluded: * A clinical diagnosis of AIDS, according to the 1993 Centers for Disease Control (CDC) AIDS surveillance definition. (CD4 cell counts below 200 cells/mm3 will not be considered AIDS-defining.) * History of allergy to any study drug. Prior Medication: Excluded: * History of antiretroviral use. Patients with a history of sequential nucleoside monotherapy will be excluded, as will patients with a total antiretroviral history exceeding 6 months. * Required treatment with immunomodulating agents, such as systemic corticosteroids, interleukins, vaccines, or interferons, within 4 weeks prior to study entry, or an HIV immunotherapeutic vaccine within 3 months prior to entry. Asthmatic patients using inhaled corticosteroids are eligible for enrollment. Prior Treatment: Excluded: Radiation therapy or cytotoxic chemotherapeutic agents received within 4 weeks prior to entry. Risk Behavior: Excluded: Current alcohol or illicit drug use which may interfere with the ability to comply with dosing schedule and protocol evaluation and assessment.